← Leaderboards
George Wilding
University Of Wisconsin Madison
$32,976,854
Attributed
$32,976,854
Total exposure
69
Grants
45
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $7.1M · FY2005–17$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$90,250,009 · 70
By mechanism
P30$80,009,538 · 29
U01$5,846,589 · 1
M01$2,321,174 · 34
T32$1,620,585 · 1
R21$208,940 · 1
P50$143,183 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of Wisconsin Madison
Same institution · by research overlap
- Howard H Bailey$27,057,671
- Caroline Margaret Alexander$5,892,984
- Yousif H Matloub$547,398
- Janet E Mertz$9,069,554
- Paul F Lambert$39,159,443
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchComprehensive Cancer CenterResearch PersonnelProgramsCancer CenterMalignant NeoplasmsWisconsinHuman SubjectMissionHuman Therapy EvaluationInstructionMemberClinical Trial Phase IUniversitiesGrantFundingServicesResourcesNeoplasm /Cancer ChemotherapyDrug Screening /EvaluationPharmacokineticsFutureAntineoplasticsEvaluation
Grant awards (200)
Developmental Funds$454,001
P30 · FY2017 · CA · contact PI
Administration$380,730
P30 · FY2017 · CA · contact PI
Cancer Informatics Shared Resource$318,857
P30 · FY2017 · CA · contact PI
Biostatistics Shared Resource$314,833
P30 · FY2017 · CA · contact PI
Human Cancer Virology Program$306,942
P30 · FY2017 · CA · contact PI
Senior Leadership$261,216
P30 · FY2017 · CA · contact PI
Clinical Research Coordinating Office$194,720
P30 · FY2017 · CA · contact PI
Data and Safety Monitoring/ NIH Policy$190,312
P30 · FY2017 · CA · contact PI
Translational Science BioCore$172,354
P30 · FY2017 · CA · contact PI
Flow Cytometry$170,345
P30 · FY2017 · CA · contact PI
Protocol Review and Monitoring System$169,414
P30 · FY2017 · CA · contact PI
Small Animal Imaging Facility$166,650
P30 · FY2017 · CA · contact PI
Experimental Pathology$157,210
P30 · FY2017 · CA · contact PI
Analytical Instrument Lab for Pharmacokinetics Pharmacodynamics Pharmacogenetics$147,346
P30 · FY2017 · CA · contact PI
Transgenic and Mutant Animal Facility$143,800
P30 · FY2017 · CA · contact PI
Survey Research$142,764
P30 · FY2017 · CA · contact PI
Small Molecule Screening and Synthesis Facility$141,496
P30 · FY2017 · CA · contact PI
Pharmaceutical Research Center$131,243
P30 · FY2017 · CA · contact PI
Planning and Evaluation$125,092
P30 · FY2017 · CA · contact PI
Protocol-Specific Research Support$119,710
P30 · FY2017 · CA · contact PI
Staff Investigator: Ryan J. Mattison, M.D.$79,461
P30 · FY2017 · CA · contact PI
Developmental Funds$463,517
P30 · FY2016 · CA · contact PI
Administration$387,456
P30 · FY2016 · CA · contact PI
Cancer Informatics Shared Resource$323,224
P30 · FY2016 · CA · contact PI
Biostatistics Shared Resource$319,045
P30 · FY2016 · CA · contact PI
Human Cancer Virology Program$310,850
P30 · FY2016 · CA · contact PI
Senior Leadership$263,390
P30 · FY2016 · CA · contact PI
Clinical Research Coordinating Office$194,360
P30 · FY2016 · CA · contact PI
Data and Safety Monitoring/ NIH Policy$189,786
P30 · FY2016 · CA · contact PI
Translational Science BioCore$171,138
P30 · FY2016 · CA · contact PI
Flow Cytometry$169,052
P30 · FY2016 · CA · contact PI
Protocol Review and Monitoring System$168,089
P30 · FY2016 · CA · contact PI
Small Animal Imaging Facility$165,217
P30 · FY2016 · CA · contact PI
Experimental Pathology$155,417
P30 · FY2016 · CA · contact PI
Analytical Instrument Lab for Pharmacokinetics Pharmacodynamics Pharmacogenetics$145,177
P30 · FY2016 · CA · contact PI
Transgenic and Mutant Animal Facility$141,498
P30 · FY2016 · CA · contact PI
Survey Research$140,422
P30 · FY2016 · CA · contact PI
Small Molecule Screening and Synthesis Facility$139,106
P30 · FY2016 · CA · contact PI
Pharmaceutical Research Center$128,461
P30 · FY2016 · CA · contact PI
Planning and Evaluation$122,082
P30 · FY2016 · CA · contact PI
Protocol-Specific Research Support$116,495
P30 · FY2016 · CA · contact PI
Staff Investigator: Ryan J. Mattison, M.D.$74,714
P30 · FY2016 · CA · contact PI
Developmental Funds$463,516
P30 · FY2015 · CA · contact PI
Administration$387,456
P30 · FY2015 · CA · contact PI
Cancer Informatics Shared Resource$323,224
P30 · FY2015 · CA · contact PI
Biostatistics Shared Resource$319,045
P30 · FY2015 · CA · contact PI
Human Cancer Virology Program$310,851
P30 · FY2015 · CA · contact PI
Senior Leadership$263,390
P30 · FY2015 · CA · contact PI
Clinical Research Coordinating Office$194,358
P30 · FY2015 · CA · contact PI
Data and Safety Monitoring/ NIH Policy$189,786
P30 · FY2015 · CA · contact PI
Translational Science BioCore$171,138
P30 · FY2015 · CA · contact PI
Flow Cytometry$169,054
P30 · FY2015 · CA · contact PI
Protocol Review and Monitoring System$168,089
P30 · FY2015 · CA · contact PI
Small Animal Imaging Facility$165,217
P30 · FY2015 · CA · contact PI
Experimental Pathology$155,418
P30 · FY2015 · CA · contact PI
Analytical Instrument Lab for Pharmacokinetics Pharmacodynamics Pharmacogenetics$145,178
P30 · FY2015 · CA · contact PI
Transgenic and Mutant Animal Facility$141,499
P30 · FY2015 · CA · contact PI
Survey Research$140,422
P30 · FY2015 · CA · contact PI
Small Molecule Screening and Synthesis Facility$139,106
P30 · FY2015 · CA · contact PI
Pharmaceutical Research Center$128,461
P30 · FY2015 · CA · contact PI
Planning and Evaluation$122,081
P30 · FY2015 · CA · contact PI
Protocol-Specific Research Support$116,495
P30 · FY2015 · CA · contact PI
Staff Investigator: Ryan J. Mattison, M.D.$74,712
P30 · FY2015 · CA · contact PI
Developmental Funds$446,768
P30 · FY2013 · CA · contact PI
Administration$373,456
P30 · FY2013 · CA · contact PI
Cancer Informatics Shared Resource$311,544
P30 · FY2013 · CA · contact PI
Biostatistics Shared Resource$307,516
P30 · FY2013 · CA · contact PI
Human Cancer Virology Program$299,616
P30 · FY2013 · CA · contact PI
Senior Leadership$253,873
P30 · FY2013 · CA · contact PI
Validation of Biomarkers to Distinguish Aggressive from Indolent Prostate Cancer$208,940
R21 · FY2013 · CA · contact PI
Clinical Research Coordinating Office$187,336
P30 · FY2013 · CA · contact PI
Data and Safety Monitoring/ NIH Policy$182,929
P30 · FY2013 · CA · contact PI
Translational Science BioCore$164,953
P30 · FY2013 · CA · contact PI
Flow Cytometry$162,943
P30 · FY2013 · CA · contact PI
Protocol Review and Monitoring System$162,016
P30 · FY2013 · CA · contact PI
Small Animal Imaging Facility$159,246
P30 · FY2013 · CA · contact PI
Experimental Pathology$149,800
P30 · FY2013 · CA · contact PI
Analytical Instrument Lab for Pharmacokinetics Pharmacodynamics Pharmacogenetics$139,930
P30 · FY2013 · CA · contact PI
Transgenic and Mutant Animal Facility$136,385
P30 · FY2013 · CA · contact PI
Survey Research$135,347
P30 · FY2013 · CA · contact PI
Small Molecule Screening and Synthesis Facility$134,079
P30 · FY2013 · CA · contact PI
Pharmaceutical Research Center$123,819
P30 · FY2013 · CA · contact PI
CRCHD$122,414
P30 · FY2013 · CA · contact PI
Planning and Evaluation$117,671
P30 · FY2013 · CA · contact PI
Protocol-Specific Research Support$112,286
P30 · FY2013 · CA · contact PI
Staff Investigator: Ryan J. Mattison, M.D.$72,015
P30 · FY2013 · CA · contact PI
UW Comprehensive Cancer Center Support$37,429
P30 · FY2013 · CA · contact PI
UW Comprehensive Cancer Center Support$4,555,705
P30 · FY2012 · CA · contact PI
UW Comprehensive Cancer Center Support$139,989
P30 · FY2012 · CA · contact PI
UW Comprehensive Cancer Center Support$74,854
P30 · FY2012 · CA · contact PI
UW Comprehensive Cancer Center Support$4,555,705
P30 · FY2011 · CA · contact PI
Developmental Funds$689,362
P30 · FY2011 · CA · contact PI
Senior Leadership$256,550
P30 · FY2011 · CA · contact PI
UW Comprehensive Cancer Center Support$139,926
P30 · FY2011 · CA · contact PI
Planning and Evaluation$83,711
P30 · FY2011 · CA · contact PI
UW Comprehensive Cancer Center Support$74,970
P30 · FY2011 · CA · contact PI
Staff Investigators$9,828
P30 · FY2011 · CA · contact PI
UW Comprehensive Cancer Center Support$4,795,480
P30 · FY2010 · CA · contact PI
Developmental Funds$692,163
P30 · FY2010 · CA · contact PI
Early Clinical Trials of New Anti-Cancer Agents with Phase 1 Emphasis (U01)$617,326
U01 · FY2010 · CA · contact PI
Senior Leadership$278,538
P30 · FY2010 · CA · contact PI
UW Comprehensive Cancer Center Support$148,912
P30 · FY2010 · CA · contact PI
Planning and Evaluation$103,840
P30 · FY2010 · CA · contact PI
UW Comprehensive Cancer Center Support$101,020
P30 · FY2010 · CA · contact PI
Staff Investigators$9,755
P30 · FY2010 · CA · contact PI
UW Comprehensive Cancer Center Support$4,736,061
P30 · FY2009 · CA · contact PI
Developmental Funds$657,096
P30 · FY2009 · CA · contact PI
Early Clinical Trials of New Anti-Cancer Agents with Phase 1 Emphasis (U01)$603,960
U01 · FY2009 · CA · contact PI
Senior Leadership$270,814
P30 · FY2009 · CA · contact PI
Planning and Evaluation$98,567
P30 · FY2009 · CA · contact PI
UW Comprehensive Cancer Center Support$59,955
P30 · FY2009 · CA · contact PI
UW Comprehensive Cancer Center Support$49,994
P30 · FY2009 · CA · contact PI
Staff Investigators$9,250
P30 · FY2009 · CA · contact PI
UW Comprehensive Cancer Center Support$4,795,480
P30 · FY2008 · CA · contact PI
Developmental Funds$649,613
P30 · FY2008 · CA · contact PI
Early Clinical Trials of New Anti-Cancer Agents with Phase 1 Emphasis (U01)$589,466
U01 · FY2008 · CA · contact PI
Senior Leadership$274,247
P30 · FY2008 · CA · contact PI
Planning and Evaluation$97,449
P30 · FY2008 · CA · contact PI
UW Comprehensive Cancer Center Support$59,955
P30 · FY2008 · CA · contact PI
Staff Investigators$9,150
P30 · FY2008 · CA · contact PI
UW Comprehensive Cancer Center Support$4,748,000
P30 · FY2007 · CA · contact PI
Developmental Funds$689,578
P30 · FY2007 · CA · contact PI
Early Clinical Trials of New Anti Cancer Agents$558,617
U01 · FY2007 · CA · contact PI
Senior Leadership$295,302
P30 · FY2007 · CA · contact PI
Physician Scientist Training in Cancer Medicine$269,962
T32 · FY2007 · CA · contact PI
UW Comprehensive Cancer Center Support$239,556
P30 · FY2007 · CA · contact PI
Mechanisms for Acquired Changes in Prostate Growth Regulaion$143,183
P50 · FY2007 · DK · contact PI
Planning and Evaluation$103,443
P30 · FY2007 · CA · contact PI
UW Comprehensive Cancer Center Support$56,723
P30 · FY2007 · CA · contact PI
Staff Investigators$9,712
P30 · FY2007 · CA · contact PI
PHASE I PK AND PD STUDY OF CCI-779 IN ADVANCED MALIGNANCIES$3,662
M01 · FY2007 · RR · contact PI
PHASE I STUDY OF TRIAPINE IN COMBINATION WITH DOXORUBICIN IN REFRACTORY TUMORS$2,922
M01 · FY2007 · RR · contact PI
PHASE I STUDY OF SAHA IN COMBINATION WITH BORTEZOMIB IN ADVANCED MALIGNANCIES$2,675
M01 · FY2007 · RR · contact PI
PHASE I STUDY OF TRIAPINE IN COMBINATION WITH IRINOTECAN IN REFRACTORY TUMORS$2,536
M01 · FY2007 · RR · contact PI
PS-341 IN ADVANCED MALIGNANCIES AND VARYING DEGREES OF RENAL DYSFUNCTION$1,300
M01 · FY2007 · RR · contact PI
PHASE I PK STUDY OF BMS-247550 IN ADVANCED MALIGNANCIES AND LIVER DYSFUNCTION$1,058
M01 · FY2007 · RR · contact PI
PHASE I PS-341 IN ADVANCED MALIGNANCIES AND VARYING DEGREES OF LIVER DYSFUNCTION$354
M01 · FY2007 · RR · contact PI
NM-404 AS AN IMAGING AGENT IN PATIENTS WITH NON-SMALL CELL LUNG CANCER$104
M01 · FY2007 · RR · contact PI
UW Comprehensive Cancer Center Support$5,586,470
P30 · FY2006 · CA · contact PI
Early Clinical Trials of New Anti Cancer Agents$523,348
U01 · FY2006 · CA · contact PI
Physician Scientist Training in Cancer Medicine$367,693
T32 · FY2006 · CA · contact PI
UW Comprehensive Cancer Center Support$250,000
P30 · FY2006 · CA · contact PI
PHASE I STUDY OF TRIAPINE IN COMBINATION WITH DOXORUBICIN IN REFRACTORY TUMORS$24,203
M01 · FY2006 · RR · contact PI
PHASE I STUDY OF TRIAPINE IN COMBINATION WITH IRINOTECAN IN REFRACTORY TUMORS$19,549
M01 · FY2006 · RR · contact PI
PHASE I G3139 IN COMBINATION WITH CARBOPLATIN AND PACLITAXEL IN SOLID TUMORS$17,997
M01 · FY2006 · RR · contact PI
PHASE I PS-341 IN ADVANCED MALIGNANCIES AND VARYING DEGREES OF LIVER DYSFUNCTION$10,861
M01 · FY2006 · RR · contact PI
PHASE I STUDY OF SAHA IN COMBINATION WITH BORTEZOMIB IN ADVANCED MALIGNANCIES$6,826
M01 · FY2006 · RR · contact PI
PHASE I PK STUDY OF BMS-247550 IN ADVANCED MALIGNANCIES AND LIVER DYSFUNCTION$3,724
M01 · FY2006 · RR · contact PI
PS-341 IN ADVANCED MALIGNANCIES AND VARYING DEGREES OF RENAL DYSFUNCTION$3,103
M01 · FY2006 · RR · contact PI
A RANDOMIZED CONTROLLED PHASE II CLINICAL TRIAL OF MODULATION OF INTER-261095130$0
N01 · FY2006 · CA · contact PI
UW Comprehensive Cancer Center Support$5,586,470
P30 · FY2005 · CA
Early Clinical Trials of New Anti Cancer Agents$532,634
U01 · FY2005 · CA
Physician Scientist Training in Cancer Medicine$225,301
T32 · FY2005 · CA
PHASE I STUDY OF MEDI 522 IN PATIENTS WITH ADVANCED TUMORS$32,958
M01 · FY2005 · RR
PHASE I STUDY OF OXALIPLATIN, 5-FU AND LV IN COMBINATION WITH ORAL CAPECITABINE$14,981
M01 · FY2005 · RR
PHASE I G3139 IN COMBINATION WITH CARBOPLATIN AND PACLITAXEL IN SOLID TUMORS$10,862
M01 · FY2005 · RR
PHASE I PK STUDY OF BMS-247550 IN ADVANCED MALIGNANCIES AND LIVER DYSFUNCTION$7,865
M01 · FY2005 · RR
PHASE I STUDY OF TRIAPINE IN COMBINATION WITH IRINOTECAN IN REFRACTORY TUMORS$7,865
M01 · FY2005 · RR
PS-341 IN ADVANCED MALIGNANCIES AND VARYING DEGREES OF RENAL DYSFUNCTION$7,491
M01 · FY2005 · RR
PHASE I STUDY OF TRIAPINE IN COMBINATION WITH DOXORUBICIN IN REFRACTORY TUMORS$2,247
M01 · FY2005 · RR
UW Comprehensive Cancer Center Support$5,450,317
P30 · FY2004 · CA
Early Clinical Trials of New Anti Cancer Agents$539,152
U01 · FY2004 · CA
UW Comprehensive Cancer Center Support$247,043
P30 · FY2004 · CA
Phase I Study of Medi 522 in Patients with Advanced Tumors$188,350
M01 · FY2004 · RR
PS-341 in Advanced Malignancies and Varying Degrees of Renal Dysfunction$41,022
M01 · FY2004 · RR
PS-341 in Combination with Doxorubicin in Patients with Advanced Solid Tumors$17,333
M01 · FY2004 · RR
Phase I Study of Oxaliplatin, 5-FU and LV in Combination with Oral Capecitabine$15,600
M01 · FY2004 · RR
Phase I STI571 in Advanced Malignancies and Varying Degrees of Renal Dysfunction$13,866
M01 · FY2004 · RR
UW Comprehensive Cancer Center Support$5,307,818
P30 · FY2003 · CA
Early Clinical Trials of New Anti Cancer Agents$530,594
U01 · FY2003 · CA
UW Comprehensive Cancer Center Support$247,043
P30 · FY2003 · CA
PHYSICIAN SCIENTIST TRAINING IN CANCER MEDICINE$148,130
T32 · FY2003 · CA
The Role of JunD in Androgen-Induced Changes in Prostate Gland Redox State$0
P50 · FY2003 · DK
UW Comprehensive Cancer Center Support$5,265,709
P30 · FY2002 · CA
PHASE I TRIALS OF ANTICANCER AGENTS$454,291
U01 · FY2002 · CA
PHYSICIAN SCIENTIST TRAINING IN CANCER MEDICINE$219,251
T32 · FY2002 · CA
PHASE I CLINICAL TRIAL OF REBECCAMYCIN$106,600
M01 · FY2002 · RR
PHASE I TRIAL OF PERILLYL ALCOHOL$106,600
M01 · FY2002 · RR
PHASE I TRIAL OF DIETHYLHOMOSPERMINE$106,600
M01 · FY2002 · RR
PHASE II TRIAL OF FLAVOPIRIDOL IN METASTATIC ANDROGEN INDEPENDENT PRO$106,600
M01 · FY2002 · RR
PHASE I BIOEQUIVALENCE STUDY OF 776C85/5 FU COMBINATION/INDIVIDUAL TABLETS$106,600
M01 · FY2002 · RR
PHASE I, ASCENDING DOSE TOLERANCE STUDY OF AG3340 IN ADVANCED CANCER$106,600
M01 · FY2002 · RR
PHASE I TRIAL OF ORAL PENCLOMEDINE$106,600
M01 · FY2002 · RR
PHASE I TRIAL OF PERILLYL ALCOHOL TWO WEEKS ON AND TWO WEEKS OFF$106,600
M01 · FY2002 · RR
CORE--ANALYTICAL INSTRUMENTATION$0
P30 · FY2002 · CA
PHASE I TRIALS OF ANTICANCER AGENTS$441,406
U01 · FY2001 · CA
PHASE I, ASCENDING DOSE TOLERANCE STUDY OF AG3340 IN ADVANCED CANCER$106,600
M01 · FY2001 · RR
PHASE II TRIAL OF FLAVOPIRIDOL IN METASTATIC ANDROGEN INDEPENDENT PRO$106,600
M01 · FY2001 · RR
PHASE I BIOEQUIVALENCE STUDY OF 776C85/5 FU COMBINATION/INDIVIDUAL TABLETS$106,600
M01 · FY2001 · RR
PHASE I TRIAL OF ORAL PENCLOMEDINE$106,600
M01 · FY2001 · RR
PHASE I TRIAL OF PERILLYL ALCOHOL TWO WEEKS ON AND TWO WEEKS OFF$106,600
M01 · FY2001 · RR
PHASE I TRIAL OF PERILLYL ALCOHOL$106,600
M01 · FY2001 · RR
PHASE I TRIAL OF DIETHYLHOMOSPERMINE$106,600
M01 · FY2001 · RR
PHASE I CLINICAL TRIAL OF REBECCAMYCIN$106,600
M01 · FY2001 · RR
PHYSICIAN SCIENTIST TRAINING IN CANCER MEDICINE$90,781
T32 · FY2001 · CA
PHASE I CLINICAL TRIAL OF REBECCAMYCIN$12,855
M01 · FY2001 · RR
PHASE I TRIAL OF PERILLYL ALCOHOL TWO WEEKS ON AND TWO WEEKS OFF$12,855
M01 · FY2001 · RR
PHASE I TRIAL OF DIETHYLHOMOSPERMINE$12,855
M01 · FY2001 · RR
PHASE II TRIAL OF FLAVOPIRIDOL IN METASTATIC ANDROGEN INDEPENDENT PRO$12,855
M01 · FY2001 · RR
PHASE I BIOEQUIVALENCE STUDY OF 776C85/5 FU COMBINATION/INDIVIDUAL TABLETS$12,855
M01 · FY2001 · RR